New study questions the need for 12 years of market exclusivity for biologics
The lengthy preclinical and clinical development necessary to bring a biologic to market has often been cited as one of the central reasons why biologics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.